USANA Health Sciences steady amid evolving wellness demand
USANA Health Sciences operates as a global provider of nutritional supplements and wellness products using a direct-selling model. The company focuses on science-based formulations and aims to build long-term relationships with distributors and customers. Investors monitor its ability to differentiate products, maintain margins, and adapt its direct-selling structure to evolving consumer behavior in a competitive market.
USANA CEO says World Cup grit mirrors everyday success habits
USANA (NYSE: USNA) Chairman and CEO Kevin Guest connects the determination of World Cup athletes to his "Piano Principle" from his book, "All the Right Reasons." He highlights five ways grit, discipline, and daily action drive success in various aspects of life. Proceeds from the book support the USANA Foundation, which aims to provide 20,000 families with meals by December 31, 2026.
Price to earnings forward of USANA Health Sciences, Inc. – NYSE:USNA
This article provides financial information for USANA Health Sciences, Inc. (NYSE: USNA), specifically focusing on its forward price-to-earnings ratio. It is presented in a data-focused format by TradingView, detailing company financials and market data.
Enterprise value to EBIT forward of USANA Health Sciences, Inc. – NYSE:USNA
This article presents financial data focusing on the enterprise value to EBIT forward for USANA Health Sciences, Inc. (NYSE: USNA). It appears to be a snapshot of financial metrics provided by TradingView, indicating the value and change over a period. The content is primarily a data point for investors or analysts interested in the company's valuation.
USANA Health Sciences, Inc.(NYSE: USNA) added to Russell Microcap Index
USANA Health Sciences, Inc. (NYSE: USNA) has been added to the Russell Microcap Index, as announced on June 28, 2026, and also to the Russell 3000E Index and Russell Microcap Value Benchmark Index on June 29. The company, a global nutrition and wellness enterprise, develops and manufactures nutritional supplements, functional foods, and personal care products. This inclusion highlights its market presence and potential growth opportunities within the microcap segment.
USANA Health Sciences, Inc.(NYSE: USNA) added to Russell 3000E Value Benchmark
USANA Health Sciences, Inc. (NYSE: USNA) has been added to the Russell 3000E Value Benchmark. This news follows other recent additions of USANA to Russell indexes, including the Russell Microcap Value Benchmark Index, Russell
USANA Health Sciences, Inc. Actuals & Estimates (NYSE:USNA)
This article provides a detailed financial overview and analyst estimates for USANA Health Sciences, Inc. (NYSE: USNA). It covers the company's stock performance, market capitalization, earnings reports, revenue, net income, and future forecasts, along with historical price data.
Usana Health Sciences CCO Neidig sells $97,303 in stock By Investing.com
Brent Neidig, Chief Commercial Officer at USANA Health Sciences Inc. (NASDAQ:USNA), sold 5,002 shares of the company’s common stock for a total of $97,303. This transaction, occurring on June 16, 2026, leaves Mr. Neidig with no direct ownership in the company. Despite the insider sale, InvestingPro analysis suggests the stock is undervalued, boasting strong gross profit margins and a solid balance sheet.
USANA Health Sciences: How The Restructuring Plan Makes It A Strong Buy
USANA Health Sciences is implementing a restructuring plan, which is causing temporary margin pressure but is expected to lead to significant future profit expansion. Despite a drop in gross margin for its Rise Wellness line due to promotional discounts and increased customer acquisition costs for Hiya, the company anticipates margin recovery and cost savings from in-house manufacturing. The author assigns USNA a Buy rating with a $30.8/share target, citing its undervaluation and strong cash position.
Insider Sell Alert: Brent Neidig Sells 5,002 Shares of Usana Hea
Brent Neidig, Chief Commercial Officer of Usana Health Sciences Inc (USNA), sold 5,002 shares of the company on June 16, 2026, and now owns zero shares. This transaction is part of a pattern where Neidig has sold 7,513 shares over the past year, with no insider purchases recorded. The stock, trading at $19.45, is considered a "Possible Value Trap" by GuruFocus, given its P/E ratio of 40.85 which is higher than industry and historical medians, and its price-to-GF-Value ratio of 0.47.
Usana Health Sciences CCO Neidig sells $97,303 in stock
Brent Neidig, Chief Commercial Officer at USANA Health Sciences Inc. (NASDAQ:USNA), sold 5,002 shares of the company’s common stock for $97,303. This transaction, revealed in an SEC filing, leaves Mr. Neidig with no direct ownership in the company. Despite the insider sale, InvestingPro analysis suggests USANA stock is undervalued given its strong balance sheet and impressive gross profit margins, aligning with recent positive financial results reported by the company for Q1 2026.
Usana Health Sciences CCO Neidig sells $97,303 in stock
Brent Neidig, CCO of USANA Health Sciences Inc., sold 5,002 shares of company stock for $97,303 on June 16, 2026, leaving him with 0 directly owned shares. This sale occurred as USANA shares have dropped about 40% over the past year. The company recently reported strong Q1 2026 financial results, exceeding earnings and revenue expectations.
[Form 4] USANA HEALTH SCIENCES INC Insider Trading Activity
USANA Health Sciences Chief Commercial Officer Brent Neidig sold 5,002 shares of common stock in an open-market transaction at a weighted average price of $19.453 per share, with prices ranging from $19.35 to $19.68. Following this sale, Neidig directly owns 0 shares of USANA Common Stock. This transaction was disclosed via a Form 4 filing, which provides transparency on insider trading activity.
USANA Health Sciences Inc (USNA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution — TradingKey
This article provides a detailed revenue breakdown for USANA Health Sciences Inc (USNA) across its business segments and geographic regions. Key segments include USANA® Nutritionals, USANA Foods, Personal Care and Skincare, and Hiya nutritional supplements, with Greater China and the Americas/Europe being significant regional contributors. The data is presented for various fiscal years and quarters, offering insight into the company's financial structure.
USANA Health Sciences Inc (USNA) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis of USANA Health Sciences Inc (USNA), focusing on its P/E ratio and overall valuation score. The company's current valuation score is 7.76, placing it 67th out of 95 in the Food & Tobacco industry. Its P/E ratio stands at 37.14, which is noted as being below its recent high but significantly above its recent low.
USANA Celebrates 10 Years of Making the World a Better Place During World Service Week
USANA Health Sciences is celebrating its 10th World Service Week, an annual event where the USANA community performs acts of service globally. This year, USANA is encouraging Brand Partners to donate to their "20,000 Families Fed" goal. The initiative marks a decade of significant community impact through various volunteer activities, strengthening vulnerable families and supporting local organizations worldwide.
Insider Sell Alert: Brent Neidig Sells Shares of Usana Health Sc
Brent Neidig, Chief Commercial Officer of Usana Health Sciences Inc (USNA), recently sold 2,511 shares, reducing his holdings to 5,002 shares. This transaction follows a pattern of 17 insider sells over the past year with no insider buys. The stock is currently trading at $20.10, showing a "Possible Value Trap" with a price-to-GF-Value ratio of 0.49, suggesting it is significantly undervalued according to GuruFocus's intrinsic value estimate.
USNA: Broker-dealer files Form 144 showing 1,602-share sale (USNA)
Morgan Stanley Smith Barney LLC Executive Financial Services has filed a Form 144 for USANA Health Sciences Inc. (USNA), reporting a proposed sale of restricted shares and a prior sale of 1,602 shares. The filing lists restricted stock items dated February 7, 2026 (220 shares) and February 8, 2026 (689 shares), along with a sale on June 12, 2026, totaling $32,280.30. This procedural filing indicates planned or recent transactions by a broker-dealer rather than corporate actions.
Insider sells 2,511 shares at USNA (USNA)
Brent Lowell Neidig, an insider at USANA Health Sciences Inc. (USNA), reported the sale of 2,511 shares through a Form 144 SEC filing. The sales occurred on June 12, 2026, totaling 1,602 shares for $32,280.30, and on June 15, 2026, totaling 909 shares for $18,184.82. The filing also disclosed earlier restricted stock issuances to Neidig in February 2026, comprising 1,248 shares and 3,754 shares respectively.
[Form 4] USANA HEALTH SCIENCES INC Insider Trading Activity
USANA Health Sciences' Chief Commercial Officer, Brent Neidig, reported two open-market sales of common stock. On June 12, 2026, he sold 1,602 shares at $20.15 per share, and on June 15, 2026, he sold an additional 909 shares at $20.005 per share. Following these transactions, Neidig directly holds 5,002 shares of USANA common stock, indicating routine personal portfolio management.
USANA (USNA) chief people officer sells 5,561 shares, exits stake
USANA Health Sciences' Chief People Officer, Paul A. Jones, sold 5,561 shares of the company's common stock at $18.50 per share in an open-market transaction. Following this sale, Jones no longer holds any direct shares in USANA. This transaction, categorized as a moderate impact with negative sentiment, was reported via a Form 4 filing.
Paul A. Jones sells 6,813 USNA shares; broker Morgan Stanley (USNA)
Paul A. Jones reported a sale of 6,813 shares of USANA Health Sciences (USNA) common stock on May 28, 2026, for $129,106.35, with Morgan Stanley Smith Barney LLC acting as the broker. The Form 144 filing also details three restricted stock issuances from the issuer in February 2026, totaling 5,561 shares. This transaction is categorized as a routine transfer and sale disclosure.
USANA Honored at Canadian Beauty Awards
USANA Health Sciences, Inc. has been recognized at The Beauty Awards Canada for its Celavive Contouring Face & Neck Crème, which was named Best Neck & Décolleté Cream of 2026. The product was praised for its innovative science, including ingredients like Feminage, BioPeptide-CS, Olivol24, and antioxidants, designed to promote skin elasticity and a youthful complexion. This prestigious award highlights Celavive's standing among Canada's top beauty products, especially in a challenging skincare category.
USANA's Celavive Contouring Face & Neck Crème Named Among Canada's Top Skincare Products
USANA Health Sciences announced that its Celavive Contouring Face & Neck Crème won in the Best Neck & Décolleté Cream category at The Beauty Awards Canada. This recognition highlights the product's innovative science and luxurious experience, helping visibly lift, firm, and smooth skin. The crème is specifically designed for women aged 35 and older, featuring clinically studied ingredients like Feminage and BioPeptide-CS.
Earnings call transcript: USANA Health Sciences beats Q1 2026 expectations
USANA Health Sciences (USNA) reported Q1 2026 earnings per share of $0.61, significantly surpassing the forecast of $0.40, and revenue of $250 million, exceeding the expected $240.95 million. The company's stock price increased by 2.6% following the announcement, reflecting investor confidence in its strategic transformation to an omnichannel health and wellness platform. USANA reaffirmed its full-year 2026 net sales guidance and highlighted strong performance in its core nutritional business, as well as growth in its Hiya and Rise Wellness segments.
One supplement just earned a Utah Best of State title for the 10th year
USANA (NYSE:USNA) has earned two 2026 Best of State awards in Utah, specifically for its CellSentials dietary supplements and its Research and Development team. This marks the tenth consecutive year CellSentials has won the Dietary Supplement award and the eighth time for the R&D team, contributing to USANA's total of over 900 awards since 1992. These awards recognize the company's commitment to scientific rigor, innovation, and quality in its product development.
Usana director John Fleming sells $43,928 in company stock
USANA Health Sciences Inc. director John Turman Fleming sold 2,450 shares of company stock for $43,928 on June 1, 2026, reducing his direct holdings to 4,230 shares. This insider sale follows the company's strong Q1 2026 financial results which exceeded analyst expectations. Despite the sale, management has been actively buying back shares, and the company recently elected eight directors to its board.
Director at USANA (NYSE: USNA) sells 2,450 shares at $17.93
USANA Health Sciences director John Turman Fleming sold 2,450 shares of the company's common stock at $17.93 per share in an open-market transaction. Following the sale, Fleming directly holds 4,230 shares, indicating he maintains a significant stake in USANA. This transaction is categorized as a net-sell event, with no derivative positions reported.
Each USANA CEO's wellness book funds 40 meals for hungry kids
USANA Chairman and CEO Kevin Guest is promoting professional wellness during June, emphasizing that healthier habits lead to stronger performance, cultures, and communities. His book, "All the Right Reasons," supports the USANA Foundation, with each purchase providing 40 meals for hungry children. The foundation has already provided over 112 million meals and aims to feed 20,000 families by the end of 2026.
USANA Health Sciences Chief People Officer Paul Jones Sells 55% Of Holding
USANA Health Sciences Chief People Officer Paul Jones recently sold 55% of his holdings in the company. This significant transaction provides insight into executive stock movements.
USANA Health Sciences Chief People Officer Paul Jones Sells 55% Of Holding
USANA Health Sciences Chief People Officer Paul Jones recently sold US$129k worth of shares, reducing his holding by 55%. This insider sale was the largest by an individual insider in the last year and occurred at a price close to the current market value, raising some caution. Despite substantial insider ownership (41%), the recent selling activity and lack of buying by insiders might dampen investor confidence, although the company has been noted for its flawless balance sheet and fair valuation.
USANA Health Sciences Chief People Officer Paul Jones Sells 55% Of Holding
USANA Health Sciences' Chief People Officer, Paul Jones, recently sold US$129k worth of shares, reducing his holding by 55%. This insider sale at around the current price of US$18.30 raises some caution among investors, although the company still boasts 41% insider ownership. No insider buying has been observed over the past year.
Usana Health Sciences CPO Paul Jones sells $129,106 of stock By Investing.com
Paul Jones, Chief People Officer at USANA Health Sciences Inc. (NYSE:USNA), sold 6,813 shares of company stock for a total of $129,106. This transaction occurred on May 28, 2026, with the shares sold at $18.95 each. Despite the insider sale, InvestingPro suggests the stock is undervalued, and the company recently reported strong Q1 2026 financial results, exceeding earnings and revenue expectations.
USANA (USNA) Chief People Officer sells 6,813 shares, retains 5,561
USANA Health Sciences' Chief People Officer, Paul A. Jones, sold 6,813 shares of common stock in an open-market transaction at $18.95 per share, totaling $129,106. Following this sale, Jones directly holds 5,561 shares of USANA stock. The transaction was reported via a Form 4 filing, indicating a negative market sentiment and a moderate impact, as he is a net seller.
Usana Health Sciences CFO sells $100,513 in company stock
G. Doug Iiekking, CFO of USANA Health Sciences Inc. (NASDAQ:USNA), sold 5,360 shares of the company's common stock for approximately $100,513. This transaction reduced his ownership to 0 shares, as reported in an SEC filing. The company recently reported strong Q1 2026 financial results, exceeding earnings and revenue expectations, and also elected new directors to its board.
USNA (NYSE) Form 144: Restricted stock sale notices including 1,775 shares
USANA Health Sciences Inc. (USNA) has filed a Form 144, indicating proposed sales of restricted common stock. The filing details multiple lots of shares, including 1,775 shares dated February 8, 2025, and 1,420 shares dated February 6, 2025, with Morgan Stanley Smith Barney LLC designated as the broker-dealer and NYSE as the principal market. This document serves as a regulatory notice of intent to sell, rather than a confirmation of completed transactions.
Usana Health Sciences CFO sells $100,513 in company stock
G. Doug Iiekking, CFO of USANA Health Sciences Inc., sold 5,360 shares of company stock for approximately $100,513 on May 27, 2026, leaving him with 0 shares. This transaction occurred as the stock trades near its 52-week low. Despite the stock performance, the company recently reported strong financial results for Q1 2026, exceeding revenue and EPS expectations.
USANA (NYSE: USNA) CFO sells 5,360 Common Stock shares in market trade
USANA Health Sciences' Chief Financial Officer, Doug G. IIEKKING, sold 5,360 shares of the company's Common Stock in an open-market transaction at an average price of $18.7525 per share. Following this sale, IIEKKING holds zero directly owned Common Stock shares, indicating a significant change in his personal investment in the company. The transaction, classified as a stock sale, was reported in an SEC Form 4 filing, providing transparency regarding insider trading activity.
USNA (NYSE) broker files Form 144 listing planned restricted-stock dispositions
Morgan Stanley Smith Barney LLC has submitted a Form 144 notice on behalf of USANA Health Sciences Inc. (USNA), detailing proposed dispositions of restricted common stock. The filing outlines planned sales on four specific dates in February 2026, totaling 5,360 shares. This notice indicates an intent to sell, and the actual execution of these sales will depend on subsequent transactions and market conditions.
Usana Health Sciences director Gilbert A. Fuller sells $19,728 in stock
Gilbert A. Fuller, a director at USANA Health Sciences Inc. (USNA), sold 1,057 shares of company stock for $19,728 on May 22, 2026, leaving him with 0 direct shares. This sale follows a 36% decline in USANA's stock over the past year. Despite the stock performance, the company reported strong Q1 2026 financial results, surpassing earnings and revenue expectations, and holds more cash than debt.
USANA (NYSE: USNA) director Fuller sells 1,057 common shares
USANA Health Sciences director Gilbert A. Fuller sold 1,057 shares of USANA common stock on May 22, 2026, at a weighted average price of $18.6648 per share. Following this open-market transaction, Fuller holds zero directly owned shares of the company. The sale, detailed in a Form 4 SEC filing, represents a net sell of approximately $19,729.
Precision Trading with Usana Health Sciences Inc. (USNA) Risk Zones
This article provides a precision trading analysis for Usana Health Sciences Inc. (USNA), highlighting a strong near-term sentiment that could challenge persistent mid and long-term weakness. It identifies a significant risk-reward short setup and outlines specific institutional trading strategies, including position, momentum breakout, and risk hedging, complete with entry zones, targets, and stop losses. The analysis is based on AI algorithms from Stock Traders Daily, offering multi-timeframe signal analysis and risk management parameters.
Precision Trading with Usana Health Sciences Inc. (USNA) Risk Zones
This article from Stock Traders Daily provides a detailed analysis of Usana Health Sciences Inc. (USNA), highlighting a near-term strong sentiment despite persistent mid and long-term weakness. It identifies an exceptional 61.5:1 risk-reward short setup and outlines three distinct institutional trading strategies based on AI models: Position Trading, Momentum Breakout, and Risk Hedging, each with specified entry zones, targets, and stop losses. The analysis also includes multi-timeframe signal analysis indicating support and resistance levels.
Usana Health Sciences shareholders elect board and approve auditor at annual meeting
Usana Health Sciences (NYSE:USNA) shareholders elected eight directors to its board and approved KPMG LLP as the company's independent registered public accounting firm for the 2026 fiscal year during its annual meeting. Shareholders also approved the executive compensation program on an advisory basis. The company, which recently reported strong Q1 2026 results, noted approximately 89% of issued and outstanding shares were represented at the meeting.
Usana Health Sciences shareholders elect board and approve auditor at annual meeting
Usana Health Sciences (NYSE:USNA) shareholders held their annual meeting, electing eight directors to the board, ratifying KPMG LLP as the independent auditor for fiscal year 2026, and approving the executive compensation program on an advisory basis. The company, which boasts strong gross profit margins and a healthy balance sheet, recently reported impressive financial results for Q1 2026, exceeding earnings and revenue expectations.
[8-K] USANA HEALTH SCIENCES INC Reports Material Event
USANA Health Sciences Inc. held its Annual Meeting of Shareholders on May 20, 2026, with approximately 89% of outstanding common stock represented. Shareholders elected all eight director nominees, ratified KPMG LLP as the independent registered public accounting firm for fiscal year 2026, and approved the company’s executive compensation on an advisory basis. These results indicate strong shareholder participation and support for the company's governance and compensation practices.
USANA projects $925M-$1B 2026 net sales as omnichannel mix targets over 20%
USANA Health Sciences projects net sales between $925 million and $1 billion for 2026, targeting over 20% of sales through its omnichannel strategy. The announcement indicates a strategic shift towards diversified sales channels to boost revenue growth. This outlook was shared during the company's investor day, highlighting future financial targets.
[10-Q] USANA HEALTH SCIENCES INC Quarterly Earnings Report
USANA Health Sciences Inc. (USNA) filed its Quarterly Earnings Report (10-Q) for the period ended April 4, 2026. The report details the company's financial condition, results of operations, and cash flows, highlighting a modest 0.3% increase in net sales to $250.2 million for the quarter, primarily driven by the Rise segment, despite declines in the Core Nutritional and Hiya segments. Net earnings attributable to USANA decreased by 20.1% to $7.5 million, due to a lower operating margin and higher effective tax rate.
USANA (USNA) director Peggie Pelosi awarded 6,527 restricted stock units
USANA Health Sciences director Peggie Pelosi was granted 6,527 restricted stock units (RSUs) as reported in a Form 4 filing. These RSUs represent a right to receive one share of USANA common stock each and will vest in four equal installments on specific dates in 2026 and 2027. This grant is a form of equity-based compensation and does not involve an open market purchase or sale of shares by Pelosi.
Director at USANA (NYSE: USNA) granted 6,527 restricted stock units
USANA Health Sciences director Timothy E. Wood was granted 6,527 restricted stock units (RSUs) in an equity award. Each RSU represents one share of USANA common stock, vesting in four equal 25% installments on specific dates between July 2026 and April 2027. After this grant, Wood directly holds 6,527 restricted stock units.
